Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03122782
Other study ID # ASU-2016-2
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received March 6, 2017
Last updated June 27, 2017
Start date August 1, 2017
Est. completion date January 2018

Study information

Verified date March 2017
Source Ain Shams University
Contact Radwa Ali Rasheedy, MD
Phone 01283492979
Email Radwaebed@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study Design:

Randomized Controlled Clinical Trial.

Study Population:

The study population will be a consecutive series of participants attending the Early Cancer Detection Unit (ECDU) at Ain Shams University Maternity Hospital.

80 women who are scheduled to undergo a hysteroscopic myomectomy will be included and will be randomized into two groups:

Group A: women will undergo a hysteroscopic myomectomy with the use of (TXA) Kapron in the distention medium

Group B: women will undergo hysteroscopic myomectomy with the use of placebo(normal saline in the distention medium).

Randomization will be performed using a Computer-generated randomization system.

The allocated groups will be concealed in serially-numbered sealed opaque envelopes that will only be opened after recruitment.

Patient allocation will be performed prior to the induction of anesthesia by an independent person, who will not otherwise be involved in this study.

The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium.

Therefore, this study will be a randomized double blind prospective clinical

Methodology:

1. Informed written consent obtained from the participant.

2. History

1. Personal history

2. Menstrual history

3. Detailed obstetric history

4. Surgical intervention especially uterine surgeries and any post-operative complication

5. History of drug intake, especially hormonal treatment or anticoagulant therapy.

3. Routine preoperative investigations in addition to a serum pregnancy test if pregnancy is suspected.

4. Physical examination including general, abdominal and pelvic examination.

5. Hysteroscopy will be performed in the early proliferative phase using normal saline as a distention medium.

6. Only in intervention group (TXA group) KAPRON (Tranexamic acid) will be added to the injected media.

- In intervention group 500 mg of Kapron for every 500 ml of distending media will be added.

- In the control group, placebo .i.e. ,normal saline in the same form will be injected inside every 500 ml of the distention medium.

7. The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium. Therefore, our study will be a randomized double blind prospective clinical trial.

8. Intraoperative bleeding and quality of view will be observed.

9. A blood sample will be taken from each participant in both groups after 24 hours from the end of the operation for both hemoglobin and hematocrit levels.

Types of outcome measures:

Primary outcome measures:

Estimated Blood loss defined as comparing the hematocrit and hemoglobin at base line (preoperative ) and 24 hours after surgery with the Tranexamic acid compared to the control group.

Secondary outcome measures:

The quality of view, duration of surgery, the volume of injected media, intraoperative complications and the success of the completion of the operation will be secondary outcomes.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date January 2018
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subjects must be able to understand, and read and sign the study specific informed consent after fully explanation the nature of the study .

2. Subjects exhibit submucous myoma that are completely within the endometrial cavity or extend less than 50 percent into the myometrium (type 0,i)according to European Society Of Hysteroscopy (ESH).

3. The submucous myoma are less than 4 cm in diameter

Exclusion Criteria:

1. Pregnancy

2. Active Pelvic Infection

3. Present or History of Cervical or Uterine Caner

4. Bleeding Diathesis or patient on anticoagulant

5. Contraindication and /or allergy to medication specified in the treatment protocol

6. History of ischemic heart disease

7. Patient with Cardiopulmonary, Hepatic , and renal diseases

8. Patient with metabolic disorders including diabetes

9. Patients with uterine septum or structural abnormality

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Topical application Tranexamic acid
Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
Placebo (Normal saline)
5ml of normal saline will be added to every 500 ml of distension media

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Outcome

Type Measure Description Time frame Safety issue
Primary Estimated blood loss by comparing changes in hemoglobin level Estimated blood loss by comparing changes in hemoglobin level before hysteroscopic myomectomy (preoperative) and 24 hours after hysteroscopic myomectomy (postoperative) in Tranexamic acid group comparing to the control group 24 Hours
Primary Estimated blood loss by comparing changes in hematocrit level Estimated blood loss by comparing changes in hematocrit level before hysteroscopic myomectomy (preoperative) and 24 hours after hysteroscopic myomectomy (postoperative) in the Tranexamic acid group comparing to the control group 24 hours
See also
  Status Clinical Trial Phase
Completed NCT04588350 - Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery N/A
Completed NCT00985920 - Topical Tranexamic Acid for Total Knee Arthroplasty Phase 4
Terminated NCT03954314 - DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery Phase 3
Completed NCT04040023 - Patient Blood Management in Cardiac Surgery N/A
Withdrawn NCT05672407 - The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery Phase 4
Not yet recruiting NCT05379530 - TEG Use in Children Undergoing Procedures With High Anticipated Blood Loss N/A
Recruiting NCT03740438 - Modeling of the Hemoglobin Drop in the Uncomplicated Postoperative Course
Completed NCT05708690 - Topical Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery Phase 4
Completed NCT04143373 - Effect of Warm Saline Irrigation on Bleeding in Mandibular Third Molar Surgery N/A
Completed NCT02996006 - New Techniques to Reduce Intra-operative Bleeding During Complex Liver Resection N/A
Completed NCT03313583 - French One Day Survey in 2011 - Knowing Our Population of Labile Blood Products Recipients N/A
Completed NCT03952546 - To Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer in Primary Unilateral Total Knee Arthroplasty N/A
Active, not recruiting NCT03426839 - Haemostasis Management of Abdominal Aortic Procedures N/A
Completed NCT05780125 - Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness Phase 2
Recruiting NCT06164769 - Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery N/A
Completed NCT04025736 - Arthroscopic Shoulder Surgery With Administration of Intravenous Tranexamic Acid N/A
Recruiting NCT02580227 - Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures Phase 4
Terminated NCT03160170 - Efficacy of Suction Enabled Retraction Device N/A
Not yet recruiting NCT06414031 - Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery Phase 3
Withdrawn NCT03340116 - Measurement of Blood Volume Loss During Burn Surgery